Search Videos and More

Showing 1 - 12 of 15 results

Previous| 1 | 2 |Next


ASH 2021 Featured Oral Presentations Document

ASH 2021 Featured Oral Presentations

The Annual Meeting of the American Society of Hematology (ASH) will take place December 11-14th. To keep-up with latest advances, the live schedule of oral presentations by Dana-Farber faculty is attached for your convenience.
Finding New Targets for Acute Myeloid Leukemia in Children News

Finding New Targets for Acute Myeloid Leukemia in Children

Looking for genes AML needs for everyday survival turned up two strong ‘hits’ to pursue for therapeutic development.
Study Results Support Stem Cell Transplantation for Older Patients with Myelodysplastic Syndromes News

Study Results Support Stem Cell Transplantation for Older Patients with Myelodysplastic Syndromes

Although stem cell transplantation is the only current therapy with the potential to cure myelodysplastic syndromes (MDS), it is rarely used as an initial treatment for older patients because it hasn’t been proven superior to other therapies. New research by Dana-Farber Cancer Institute investigators stands to overturn that practice.
Mantle Cell Lymphoma Clinical Trial Document

Mantle Cell Lymphoma Clinical Trial

Targeted combination therapy for mantle cell lymphoma with minimal residual disease assessment.
Clinical Trial Spotlight: Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL) Video

Clinical Trial Spotlight: Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)

Dr. Marlise Luskin, a specialist in the Adult Leukemia Program at Dana-Farber Cancer Institute, explains an innovative trial that combines the BCL2 inhibitor, venetoclax with chemotherapy for older patients with ALL.
Stem Cell Transplant Beneficial for Older Patients with Myelodysplastic Syndrome Video

Stem Cell Transplant Beneficial for Older Patients with Myelodysplastic Syndrome

New research shows stem cell transplant represents the best therapeutic approach for older individuals with myelodysplastic syndrome. Dana-Farber Cancer Institute's Corey Cutler, MD, MPH, FRCPC explains more.
Treatment for Adults with Acute Lymphoblastic Leukemia Video

Treatment for Adults with Acute Lymphoblastic Leukemia

Marlise Luskin, MD, MSCE, a leukemia specialist at Dana-Farber Cancer Institute describes treatment for adults with acute lymphoblastic leukemia (ALL). She explains treatment considerations for younger adults and older adults with ALL.
Newsweek Names Dana-Farber #3 in the World for Cancer News

Newsweek Names Dana-Farber #3 in the World for Cancer

Dana-Farber Cancer Institute has been named one of the world’s very best cancer hospitals by Newsweek in its new World’s Best Specialized Hospitals 2022 rankings.
Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in Immunotherapy News

Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in Immunotherapy

Despite the sometimes-dramatic success of new cancer immunotherapies like checkpoint inhibitor drugs and CAR T cells, thus far only a minority of patients have responded or gained long-lasting benefits.
In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant News

In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant

An immune-suppressing drug normally used to treat rheumatoid arthritis could make bone marrow transplant safer, report researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. In a Phase 2 multi-center trial, the drug abatacept (ORENCIA®) reduced rates of severe, acute graft-versus-host disease (GVHD) and boosted rates of survival without acute GVHD or relapse in patients with leukemia and other blood cancers.
First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients News

First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients

The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber Cancer Institute.
Dana-Farber to Offer First CAR T-Cell Therapy for Indolent Follicular Lymphoma Following FDA Approval News

Dana-Farber to Offer First CAR T-Cell Therapy for Indolent Follicular Lymphoma Following FDA Approval

The Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for indolent follicular lymphoma, a slow growing, non-Hodgkin lymphoma (NHL), represents a key advance for patients with relapsed or refractory forms of the disease. Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will be a certified treatment center for the therapy.

Showing 1 - 12 of 15 results

Previous| 1 | 2 |Next